Stocktoria
STRATA Skin Sciences, Inc. SSKN
STRATA Skin Sciences, Inc. (SSKN) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $30.7M at a -20.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.31 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SSKN | STRATA Skin Sciences, Inc. | 4/9 | — | — | -8.5% |
| OBIO | Orchestra BioMed Holdings, Inc. | 5/9 | -7.02 | — | — |
| SRTS | Sensus Healthcare, Inc. | 4/9 | 14.36 | — | -34.3% |
| CTSO | Cytosorbents Corp | 3/9 | — | — | +4.1% |
| UTMD | UTAH MEDICAL PRODUCTS INC | 3/9 | — | — | -5.8% |
| IDXG | INTERPACE BIOSCIENCES, INC. | 4/9 | -16.52 | 1.9 | -17.5% |
| BDMD | Baird Medical Investment Holdings Ltd | 1/9 | 0.49 | — | -39.2% |
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.
FAQ
Is SSKN financially healthy?
STRATA Skin Sciences, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does SSKN pay a dividend?
No, STRATA Skin Sciences, Inc. does not currently pay a dividend.
How profitable is SSKN?
In FY2025, STRATA Skin Sciences, Inc. had a net margin of -20.4% and a return on equity of -215.3%.
Is SSKN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on STRATA Skin Sciences, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.